First BTK Inhibitor Approved for Immune Thrombocytopenia

(MedPage Today) — The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday.
As the first Bruton’s tyrosine kinase (BTK) inhibitor for ITP, the indication stipulates…

Source link : https://www.medpagetoday.com/hematologyoncology/hematology/117263

Author :

Publish date : 2025-09-02 17:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

First BTK Inhibitor Approved for Immune Thrombocytopenia

Rapamycin may extend lifespans by protecting against DNA damage

Could Vaginal Microbiome Testing Transform Women’s Health?

Related Posts

Is Tylenol Linked to Infant Eczema?

Antibody Prevention of RSV in Infants; Medical Imaging and Cancer Risk in Kids

Trusted Vaccine Guidance Has Collapsed — Along With the Rule of Law

Considering GLP-1 Agonists for Patients With Psoriasis, HS

It’s Time to Get a Flu Vaccination. Here’s Who Needs One and Why.

Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say

Is Tylenol Linked to Infant Eczema?

Antibody Prevention of RSV in Infants; Medical Imaging and Cancer Risk in Kids

Trusted Vaccine Guidance Has Collapsed — Along With the Rule of Law

Considering GLP-1 Agonists for Patients With Psoriasis, HS

It’s Time to Get a Flu Vaccination. Here’s Who Needs One and Why.

Pick GLP-1s as First Drug Option in Obesity, Guidelines From Abroad Say

Ahead of Shutdown, Most Americans Said They Wanted ACA Tax Credits Extended

Medical Groups Call for Physician Exemptions to Trump’s Executive Order

Categories

Archives